Literature DB >> 12013330

3: Community-acquired pneumonia.

Paul D R Johnson1, Lou B Irving, John D Turnidge.   

Abstract

Community-acquired pneumonia is caused by a range of organisms, most commonly Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae and respiratory viruses. Chest x-ray is required for diagnosis. A risk score based on patient age, coexisting illness, physical signs and results of investigations can aid management decisions. Patients at low risk can usually be managed with oral antibiotics at home, while those at higher risk should be further assessed, and may need admission to hospital and intravenous therapy. For S. pneumoniae infection, amoxycillin is the recommended oral drug, while benzylpenicillin is recommended for intravenous use; all patients should also receive a tetracycline (eg, doxycycline) or macrolide (eg, roxithromycin) as part of initial therapy. Flucloxacillin or dicloxacillin should be added if staphylococcal pneumonia is suspected, and gentamicin or other specific therapy if gram-negative pneumonia is suspected; a third-generation cephalosporin plus intravenous erythromycin is recommended as initial therapy for severe cases. Infections that require special therapy should be considered (eg, tuberculosis, melioidosis, Legionella, Acinetobacter baumanii and Pneumocystis carinii infection).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12013330     DOI: 10.5694/j.1326-5377.2002.tb04437.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study.

Authors:  Kun Xiao; Long-Xiang Su; Bing-Chao Han; Peng Yan; Na Yuan; Jie Deng; Jia Li; Li-Xin Xie
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia.

Authors:  K L Buising; K A Thursky; J F Black; L MacGregor; A C Street; M P Kennedy; G V Brown
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

3.  Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?

Authors:  Samuel George Campbell; R Andrew McIvor; Vincent Joanis; David Graydon Urquhart
Journal:  World J Emerg Med       Date:  2011

4.  The role of complications of community acquired pneumonia on the outcome of the illness: a prospective observational study in a tertiary institution in eastern Nigeria.

Authors:  Gc Mbata; Cj Chukwuka; Cc Onyedum; Bjc Onwubere; En Aguwa
Journal:  Ann Med Health Sci Res       Date:  2013-07

Review 5.  [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features].

Authors:  F Philippart
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

6.  The Queensland experience of participation in a national drug use evaluation project, Community-Acquired Pneumonia Towards Improving Outcomes Nationally (CAPTION).

Authors:  Lisa K Pulver; Susan E Tett; Judith Coombes
Journal:  BMC Pulm Med       Date:  2009-08-03       Impact factor: 3.317

7.  Adherence to therapeutic guidelines for patients with community-acquired pneumonia in Australian hospitals.

Authors:  Nr Adler; Hm Weber; I Gunadasa; Aj Hughes; Nd Friedman
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2014-09-14

8.  Validating a novel index (SWAT-Bp) to predict mortality risk of community-acquired pneumonia in Malawi.

Authors:  Imogen M Buss; Edmund Birkhamshaw; Michael A Innes; Itai Magadoro; Peter I Waitt; Jamie Rylance
Journal:  Malawi Med J       Date:  2018-12       Impact factor: 0.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.